Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.85 |
| ▸ | CCL2 | P13500 | 3/20 | 0.72 |
| ▸ | BRD2 | P25440 | 5/20 | 0.57 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13727152 | 0.89 | BRD4 (0.89) | BRD4CCL2BRD2BRD3EP300 | |
| SCHEMBL15437469 | 0.88 | BRD4 (0.81) | BRD4CCL2BRD2BRD3EP300 | |
| SCHEMBL17594284 | 0.88 | BRD4 (0.84) | BRD4CCL2BRD2BRD3EP300 | |
| SCHEMBL19460002 | 0.88 | BRD4 (0.84) | BRD4CCL2BRD2BRD3EP300 | |
| SCHEMBL13728008 | 0.86 | BRD4 (0.84) | BRD4CCL2BRD2BRD3EP300 | |
| SCHEMBL15450317 | 0.85 | BRD4 (0.79) | BRD4CCL2BRD2BRD3 | |
| SCHEMBL13724287 | 0.84 | BRD4 (0.78) | BRD4CCL2BRD2BRD3EP300 | |
| SCHEMBL15450326 | 0.84 | BRD4 (0.77) | BRD4CCL2BRD2BRD3 | |
| SCHEMBL19459527 | 0.84 | BRD4 (1.00) | BRD4CCL2BRD2BRD3EP300 | |
| SCHEMBL15450342 | 0.84 | BRD4 (0.77) | BRD4CCL2BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142949-A1 | COVALENT CONJUGATES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-16 | — | — | US | disclosed |
| EP-3168213-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3168213-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20180117165-A1 | COVALENT CONJUGATES OF BET INHIBITORS AND ALPHA AMINO ACID ESTERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| EP-3270974-A1 | COVALENT CONJUGATES OF BET INHIBITORS AND ALPHA AMINO ACID ESTERS | GlaxoSmithKline Intellectual Property Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| EP-3168213-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-3168213-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2699551-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2699551-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-11-16 | — | — | EP | disclosed |
| WO-2016146755-A1 | COVALENT CONJUGATES OF BET INHIBITORS AND ALPHA AMINO ACID ESTERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
| EP-2699550-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140039006-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039006-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039006-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2012150234-A1 | DIHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012150234-A1 | DIHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012143413-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | BRD4, BRDT, BRD3 | BRD4 1/4885CCL2 1857/4885BRD2 4/4885 |
| US-20180117165-A1 | COVALENT CONJUGATES OF BET INHIBITORS AND ALPHA AMINO ACID ESTERS | BET1, BRD4, RABGGTB | BRD4 2/4885CCL2 857/4885BRD2 13/4885 |
| US-20190142949-A1 | COVALENT CONJUGATES | BET1, RABGGTB, BRD4 | BRD4 3/4885CCL2 417/4885BRD2 11/4885 |
| US-20140039006-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | BRD4, BRDT, BRD3 | BRD4 1/4885CCL2 1950/4885BRD2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.